SCHEMBL4945705

SCHEMBL4945705

CC(C)S(=O)(=O)Nc1ccsc1-c1ccc(-c2ccc(C(=O)CCC(=O)O)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.45
CYP1A2 P05177 2/20 0.45
FFAR1 O14842 1/20 0.45
LMNA P02545 1/20 0.45
RAB9A P51151 1/20 0.45
HIF1A Q16665 1/20 0.45
USP5 P45974 1/20 0.43
KMT2A Q03164 3/20 0.40
GRIA4 P48058 1/20 0.39
HPGD P15428 3/20 0.37
MAPT P10636 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
NR4A2 P43354 1/20 0.36
MEN1 O00255 1/20 0.34
CYP3A4 P08684 1/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP2C19 P33261 2/20 0.34
GAA P10253 1/20 0.34
PTGS1 P23219 2/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4953693 0.86 GRIA4 (0.49) GRIA4PTGS1
SCHEMBL4951060 0.85 NPSR1 (0.44) FFAR1MAPTALDH1A1MMP12
SCHEMBL4951358 0.82 ABCC4 (0.41) FFAR1LMNAKMT2AGRIA4HPGD
SCHEMBL4953413 0.80 PTGS2 (0.48) GRIA4
SCHEMBL4949928 0.80 ALDH1A1 (0.41) SMN1; SMN2CYP1A2HPGDMAPTALDH1A1
SCHEMBL4949814 0.80 HPGD (0.45) SMN1; SMN2CYP1A2LMNARAB9AKMT2A
SCHEMBL4946259 0.77 ACLY (0.45) SMN1; SMN2LMNARAB9AKMT2AGRIA4
SCHEMBL4950027 0.77 TDP1 (0.39) GRIA4L3MBTL1PTGS1
SCHEMBL4948474 0.77 RORC (0.39) CYP1A2LMNACYP3A4
SCHEMBL4950718 0.76 RARB (0.41) GRIA4L3MBTL1ALDH1A1GAAPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893597-B1 AMPA RECEPTOR POTENTIATORS LILLY CO ELI (US) 2008-11-12 EP disclosed
US-7393868-B2 AMPA receptor potentiators ELI LILLY AND COMPANY (US) 2008-07-01 US disclosed
US-20070142441-A1 AMPA receptor potentiators ELI LILLY AND COMPANY 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142441-A1 AMPA receptor potentiators GABRE, GRIN1, GRIK2 SMN1; SMN2 2557/4885CYP1A2 1856/4885FFAR1 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.